Drug General Information
Drug ID	D0G4DE
Former ID	DNC000313
Drug Name	BIA 3-202
Drug Type	Small molecular drug
Indication	Parkinson's disease [ICD9: 332; ICD10:G20]		Phase 2	[529342]
Structure		Download 2D MOL 3D MOL
Formula	C14H11NO5
Canonical SMILES	C1=CC=C(C=C1)CC(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-]
InChI	1S/C14H11NO5/c16-12(6-9-4-2-1-3-5-9)10-7-11(15(19)20)14(18)13(17)8-10/h1-5,7-8,17-18H,6H2
InChIKey	MRFOLGFFTUGAEB-UHFFFAOYSA-N
CAS Number	CAS 274925-86-9
PubChem Compound ID	9838389
PubChem Substance ID	14799384, 24137176, 44936477, 57373490, 79760348, 92729843, 103412732, 104004043, 125732769, 126601938, 128636293, 134343097, 135252377, 136345013, 137237662, 140030645, 163154452, 198940728, 226500751, 241056130
Target and Pathway
Target(s)	Catechol-O-methyl-transferase	Target Info	Inhibitor	[535563]
BioCyc Pathway	L-dopa degradation
	Dopamine degradation
	Noradrenaline and adrenaline degradation
KEGG Pathway	Steroid hormone biosynthesis
	Tyrosine metabolism
	Metabolic pathways
	Dopaminergic synapse
PANTHER Pathway	Adrenaline and noradrenaline biosynthesis
	Dopamine receptor mediated signaling pathway
PathWhiz Pathway	Tyrosine Metabolism
WikiPathways	Methylation Pathways
	Metapathway biotransformation
	Estrogen metabolism
	Biogenic Amine Synthesis
	Dopamine metabolism
	Phase II conjugation
	Neurotransmitter Clearance In The Synaptic Cleft
References
Ref 529342	Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. Clin Neuropharmacol. 2008 Jan-Feb;31(1):2-18.
Ref 535563	Chemical synthesis and characterization of conjugates of a novel catechol-O-methyltransferase inhibitor. Bioconjug Chem. 2002 Sep-Oct;13(5):1112-8.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.